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Gastrointestinal(GI)bleedingismorecommoninpatientswithchronickidneydiseaseandisassociatedwithhighermortalitythan
in the general population. Blood losses in this patient population can be quite severe at times and it is important to diﬀerentiate
anemia of chronic diseases from anemia due to GI bleeding. We review the literature on common causes of lower gastrointestinal
bleeding (LGI) inchronickidney disease(CKD) and end-stagerenaldisease(ESRD) patients.Wesuggestanapproach to diagnosis
and managementof this problem.
1.Introduction
Gastrointestinal (GI) bleeding is more common in patients
with chronic kidney disease and is associated with higher
mortality than in the general population [1]. Anemia is a
common feature of patients with chronic kidney disease [2,
3]. It is usually normocytic normochromic due to decreased
erythropoietin production and red blood cell survival. How-
ever, concomitant iron deﬁciency anemia can also exist due
to blood losses during hemodialysis, use of erythropoietin-
stimulating agents, or GI bleeding. Initial anemia work up of
these patientsshould therefore includered bloodcell indices,
absolute reticulocyte count, iron studies, peripheral blood
smear, work-up for hemolytic anemia, and an evaluation for
GI sources of blood losses if indicated. A clue to the need for
GIevaluationforbloodlossisinpatientswho arenotreplen-
ishing their iron stores despite adequate iron replacement or
who demonstrate sudden decrease in stable hemoglobin.
Physiological mechanisms contributing to an increased
bleeding tendency in ESRD patients include uremic platelet
dysfunction [4, 5],intermittentheparin use in dialysis, use of
antiplatelet agents, and anticoagulants [6].
Anemia itself promotes bleeding diathesis as circulating
red blood cells displace platelets toward the vessel wall. This
helps maintain their contact with subendothelium at sites
of injury. Red blood cells also enhance platelet function by
releasing adenosine diphosphate (ADP) and inactivating
prostacyclin (PGI) [7]. Thus evaluation of the cause of
anemia and its treatment is important for correction of the
bleeding diathesis in this patient population. Both upper
and lower GI bleeding can contribute to GI losses but this
paper will focus on causes of lower GI bleeding in CKD
patients. Figure 1 gives an algorithmic approach to diagnose
LGI bleed and Figure 2 highlights thecommoncausesofLGI
bleeding in CKD patients.
2.Discussion
Lower gastrointestinal tract bleeding is deﬁned as bleeding
that occurs distal to the ligament of Treitz. The annual
incidence rate of lower gastrointestinal bleeding in the USA
ranges from 20.5 to 27 cases per 100,000 adult population at
risk (0.03%) [8]. The annual incidence of hospitalization for
LGI bleed isestimated to be 20 to 30 per100,000persons [9].
In patients who complain of blood in the stool, 10% of cases
arise from the upper GI tract segment, proximal to the liga-
ment of Treitz, 5% from the small intestine, and 85% from
within the colon [10]. There is lack of speciﬁc data regarding2 International Journal of Nephrology
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Figure 2: Causes of LGI bleeding in CKD patients.
the distribution of GI bleeding by location in ESRD patients.
Despite the fact that most episodes of lower GI bleeding stop
spontaneously without intervention, rebleeding remains a
serious problem in 10–40% of patients [9]. Thus, in lower
GI tract bleeding, determination of the etiology is important
evenifthebleedinghasstopped.InastudyofacuteLGIbleed
in Canada, the average cost for a patient with LGI bleed was
$4,832 Canadian dollars (approximately 3,000 US dollars)
with an average length of stay of 7.5 days [11]. Important
facts about LGI bleeding in CKD patients are illustrated in
Table 1. Each of the common causes of LGI bleeding in CKD
patients is reviewed in the following section.
Angiodysplasia are vascular ectasias not associated with
any familial syndrome, cutaneous, or systemic lesions. They
are the most common vascular malformations of the gas-
trointestinal tractinthegeneralpopulationwithaprevalence
of 0.82% [12]. Most angiodysplasias occurring in the general
population are detected in patients older than 60 years ofInternational Journal of Nephrology 3
Table 1: Important facts about LGI bleed in CKD patients.
(i) Suspect GI blood loss if iron stores are not replenished despite
adequate iron replacement or if a sudden drop in stable
hemoglobin is seen.
(ii) Oral iron can cause black stools and give false positive guaiac
test in CKD patients.
(iii) Avoid phosphorus or magnesium based colonic preparations
in CKD patients [71].
age [13] although presentation in patients with CKD can be
earlier [14]. Angiodysplasias are the leading cause of recur-
rent LGI bleeding in ESRD patients, accounting for 19–32%
of LGI bleeds in those with chronic kidney disease compared
with 5-6% of LGI bleeds in the general population [12].
Angiodysplasias are most commonly located in the
cecum and ascending colon but can be identiﬁed in any por-
tion of the GI tract [15]. Histologically, angiodysplasias are
small, 5–10mm, ectatic blood vessels lined by endothelium
alone or a thin layer of smooth muscle. The etiology of angi-
odysplasia is unclear.
Angiodysplasias tend to be multiple and present with
iron deﬁciency anemia secondary to recurrent GI bleeding.
Bleeding secondary to angiodysplasia is more commonly oc-
cult and intermittent but massive bleeding can also occur.
While bleeding stops spontaneously in about 90% of cases,
the tendency to rebleed is seen in 25–47% and can be life
threateninginsomecases[16].Factorsassociatedwithrecur-
rent bleeding include high bleeding rate, supratherapeutic
anticoagulation, and multiple angiodysplastic lesions [16].
The diagnosis of angiodysplasia is mostly accomplished
using endoscopicprocedures. The typicalendoscopicallyvis-
ualized appearance is of a discrete, ﬂat or slightly raised,
bright red 5–10mm fern-like pattern of small dilated veins
radiating from a central vessel. Sensitivity of colonoscopy is
estimated to be around 81% when the lesion is located in
the colon [17]. As angiodysplasia can be located anywhere
in the GI tract, visualization of the whole bowel is required.
Upper GI endoscopy, push enteroscopy, and wireless capsule
enteroscopyare useful inthediagnosisofupperGIangiodys-
plasias. Selective mesenteric angiography can be utilized in
cases ofactive bleeding. Helical CT angiography isan emerg-
ing and promising imaging technique for the noninvasive
diagnosis of angiodysplasia and occult GI bleeding. The role
of angiography is limited due to the need for intravenous
contrast. Its utility in CKD patients applies only to cases of
activebleedingwho remain undiagnosed despiteotherinves-
tigations. Technicium- (Tc-) labeled scintigraphy is some-
times useful to detect active bleeding; however, it remains
of limited use because of the often intermittent nature of
bleeding in angiodysplasia and due to its poor sensitivity.
Angiodysplasias are treated locally with Argon plasma
coagulation (APC) [18] or bipolar/heater probe [19]. Angi-
ography may permit localization of a large bleeding lesion
with therapeutic embolization or injection of vasopressin
[20]. Estrogen, with or without progesterone, has been
prescribed in ESRD patients who are not surgical candidates
but eﬃcacy of this treatment remains controversial [21–23].
Long-term therapy with octreotide may decrease transfusion
requirements and prevent recurrence by decreasing splanch-
nic blood ﬂow [24]. Angiogenesis inhibitors have also been
described as a treatment but evidence for their role is limited
[25]. Patients with active bleeding from angiodysplasia
who are hemodynamically stable can be managed con-
servatively with ﬂuid support, and if present, correction of
bleeding diathesis and blood transfusions because 90% of
these episodes will cease bleeding spontaneously. Iron and
erythropoietin replacement needs to be considered. In con-
trast, hemodynamically unstable patients may require endo-
scopic obliteration or surgical intervention.
Diverticulosis is one of the most common causes of
LGI bleeding in ESRD patients. Diverticulosis accounts for
approximately 30–50% of cases of lower GI bleeding within
the general population [26]. Diverticulosis may not occur
with increased frequency in those who are not on dialysis
[27]. However, the incidenceof LGI bleeding dueto divertic-
ulosis in ESRD patients is the same as in the general popula-
tion.The exceptiontothis is in patientswith AdultPolycystic
Kidney Disease (APKD) who are on maintenance dialysis
and have a higherincidenceofdiverticularbleeds[23, 28].In
o n es t u d y ,t h ei n c i d e n c eo fd i v e r t i c u l o s i si nA P K Dp a t i e n t s
on hemodialysis was estimated to be around 83% [28]. In
another study, it was around 50% [29]. Incidence is propor-
tional to age with a prevalence of less than 5% at age 40
and 60–65% at the age of 80 years [28]. However, in dialysis
patients with kidney disease from any cause, diverticulosis
may occur at younger age and may be more severe [30, 31].
Diverticuliareoutpouchingsofintestinalmucosathrough
the smooth muscle layers and generally occur at the site
of penetration of the vasa recta. They are most commonly
located in the sigmoid colon and are most commonly false
diverticuli covered only by the mucosal and submucosal
layers. While the exact cause for the development of diver-
ticulosis is uncertain, intestinal dyskinesias and increased
intraluminal pressure in the colon have been postulated.
Consumption of a low ﬁber diet, constipation, and obesity
have all been described as risk factors for the developmentof
diverticulosis. Ninety percent of diverticuli are found in the
left colon, however, diverticuli from the right colon account
for 50% of bleeding [32]. They may cause abdominal pain
which may be confused with pain from renal cysts, especially
in the setting of APKD. In these patients, the incidence of
complications, like colonic perforation, is higher than in the
general population and may be increased following renal
transplant [28]. The pretransplant detection of diverticulitis
is very important, since perforation in the setting of renal
transplant carries a mortality rate of 60 percent [33]. This
high mortality is due in part to the masking of signs and
symptoms of peritonitis [34].
Diverticulosis is a noninﬂammatory condition and while
overt or occult bleeding from diverticula can be associated
with symptoms such as nausea and bloating, signs of peri-
tonitis are never consistent with diverticulosis. In cases in
which signs of peritonitis are present, diverticulitis should
be included in the diﬀerential diagnosis but diverticulitis is
rarely the cause of GI bleeding [32]. Although diverticulosis
has not been proven to be more common in patients on4 International Journal of Nephrology
peritoneal dialysis than in the general population, the pres-
ence of >10 diverticulae, diverticular size >10mm, and the
presence of diverticula in the ascending, transverse, or de-
scending colon has been associated with an increased risk
of peritonitis [35]. Colonoscopy is the initial investigation
of choice when diverticulosis is suspected [36]. No signif-
icant association has been found between the timing of col-
onoscopyand diagnosticyieldofcolonoscopy[37].Dynamic
enhanced helical CT scan can also be used if endoscopy is
not diagnostic or is not possible. It is less invasive than angi-
ography and more accurate than nuclear scintigraphy. Con-
trast-enhanced magnetic resonance angiography (MRA) has
beenassessed asaninvestigational toolfordetectingbleeding
diverticuli. In animal studies, it has demonstrated 100%
sensitivity and speciﬁcity compared with 78% sensitivity and
72% speciﬁcity for nuclear scintigraphy [38].
Management of colonic diverticular bleeding includes
volume resuscitation. Colonoscopy can be both diagnostic
and therapeutic if bleeding diverticula are identiﬁed. This is
not always possible due to the intermittent nature of bleed-
ing.Arteriographywithvasopressin infusionorembolization
is usually reserved for patients in whom endoscopy is not
feasible or those with persistent or recurrent bleeding and a
nondiagnostic colonoscopy [16]. Embolization may carry a
20% risk of infarction [39]. Exploratory laprotomy with par-
tial or total colectomy is considered the deﬁnitive diagnos-
tic test when the source of the bleeding diverticuli remains
elusive with other techniques.
Ischemic colitis arises secondary to a decrease in splanch-
nic perfusion leading totissue ischemia as well as reperfusion
injury to the bowel wall [40]. Ischemic colitis is more com-
mon in ESRD patients due to advanced atherosclerosis and
overall compromised circulatory state. In addition, hemo-
dialysis patients have a signiﬁcantly increased risk for is-
chemic colitis due to repeated episodes of hypotension and
hypovolemia associated with hemodialysis procedures [41].
Inonestudy,theincidenceofischemiccolitisinhemodialysis
patients was 0.3% per patient-year [42]a n di na n o t h e rs t u d y
ischemic colitis was the most common cause for emergent
abdominal surgery, secondary to a nonocclusive vascular
emergency [43]. Additional risk factors for nonocclusive
mesenteric ischemia in both hemodialysis and peritoneal
dialysispatientsincludeaggressive use ofrecombinanteryth-
ropoietin therapy and metastatic calciﬁcation [44–46]. A
2009 study reported three cases of nonocclusive mesenteric
ischemia in a population of 158 patients on peritoneal di-
alysis, resulting in an incidence of 1.35% per patient year. As
with hemodialysis, the development of acute mesenteric is-
chemia in patients on peritoneal dialysis may be caused by
excessive ultraﬁltration [47].
Ischemiccolitisusuallypresentsasabdominalpainwhich
can be associated with either melena or hematochezia. Ab-
dominal pain may be confused with peritonitis especially in
patients on peritoneal dialysis and may result in delay in
appropriate treatment and high mortality [44]. Abdominal
pain during orafter a hemodialysis session particularly when
associated with elevated white cell count should raise the
suspicion of ischemic colitis [48]. In one small study of
patientswithmesenteric ischemia, 87% had abdominal pain,
fever, and leukocytosis, and 47% had a marked dialysis-asso-
ciated hypotensive episode prior to the onset of ischemia.
In the general population left-sided colonic involvement is
more common but in ESRD patients, involvement of the
right side of the colon is more common and associated with
more severe disease [49, 50]. Findings consistent with an
acute abdomenportend a worse prognosis than patients pre-
senting with melena alone [51].
Diagnosis of ischemic colitis is based on the clinical pre-
sentation, presence of risk factors, and radiological and en-
doscopic tests. Colonoscopy is generally needed to establish
a deﬁnitive diagnosis. Angiography (limited role in CKD
patients) and Doppler studies can be employed in cases
in which diagnosis is diﬃcult. Treatment of acute colonic
ischemia depends upon its severity and the clinical setting.
Supportivecareincludingintravenousﬂuidstomaintaincol-
onic perfusion and bowel rest are warranted in almost all
cases. Empiric broad spectrum antibiotics can be prescribed
in moderate to severe cases. In general, embolectomy, bypass
graft, or endarterectomy are rarely used to treat colonic
ischemia as large artery obstruction is an extremely uncom-
mon cause of the ischemia. When emergent management
is required, a diagnostic laparoscopy can prove to be both
diagnostic and therapeutic.
Dialysis-related amyloidosis (DRA) may occur in patients
on long-term dialysis. In fact, complications associated with
DRA are seen in the majority of patients on dialysis for
greater than 20 years [52]. DRA is commonly associated
with musculoskeletal complications although gastrointesti-
nal involvement has also been reported. In the cases of gas-
trointestinalinvolvement,β-2microglobulindepositsmainly
within the muscularis propria of the GI tract wall. This is in
contrast to other amyloid proteins which more commonly
are deposited within the walls of the arterial system. Reduced
motility combinedwith an increased rigidity secondary to β-
2 amyloid deposition within the intestinal musculature re-
sults in shearing forces and tearing of the mucosa. Coupled
with preexisting mucosal ulcerations and coagulopathies,
these shear forces can cause signiﬁcant damage and bleeding
within the GI tract [53]. For unknown reasons, involvement
of the upper GI tract is more common than the lower GI
tract. The most frequent GI manifestation of DRA is GI
bleeding with abdominal pain. The severity of bleeding can
vary widely. Pseudo-obstruction, perforation, and necrosis
are all possible. DRA should be suspected in patients on
long-term dialysis without other obvious causes for lower GI
bleeding. Endoscopy is nonspeciﬁc and can show mucosal
folds with or without mucosal ulceration. A diagnosis of
DRA must be conﬁrmed by histological documentation of
amyloid on biopsy.
Renaltransplantation is theonlyeﬀectivetreatment [54].
Biocompatible high-ﬂux hemodialysis membranes may be
more eﬀective in removal of the protein but their use does
not prevent progression of DRA or the development of new
lesions.
Colon carcinoma and colon polyps are also important
causes of lower GI bleeding in the dialysis population al-
though colon cancer does not appear to be more common in
the dialysis population [55]. In the general population, 19%International Journal of Nephrology 5
of the cases of lower GI bleeding are attributed to colon can-
cer and polyps. The risk of colonic polyps in ESRD patients
is also not signiﬁcantly increased as compared to the general
population [55]. The speciﬁcity of screening for colon
cancer among patients with ESRD diﬀers from the general
population because dialysis patients have a high incidence of
nonmalignant gastrointestinal bleeding abnormalities mak-
ing guaiac testing misleading. In one study, the incidence of
guaiacpositivestoolswasthreetimeshigherinasymptomatic
dialysis patients compared to non-ESRD controls [56].
Stercoral ulceration of the colon is being increasingly
recognized as a cause of lower gastrointestinal (GI) tract
bleeding in the ESRD population [57]. Pressure induced
by hard, large fecal masses induces necrosis and ulceration
of colonic mucosa known as stercoral ulcers. There can be
single or multiple lesions which can occur throughout the
colonbutusuallyoccurwithin thesigmoidcolonandrectum
[58]. Chronic constipation is the major risk factor for the
development of stercoral ulcers. Dialysis patients are more
prone to constipation due to phosphate binders such as sele-
vemer [59], ﬂuid restriction, and inactivity as well as slowed
bowel motility. Grossly, stercoral ulcersare irregular in shape
and sharply delineated from the surrounding colonic muco-
sa. Microscopically the lesions vary in depth from mucosal
ulceration to transmural perforation. Areas with transmural
involvement are at the greatest risk of perforation. Chronic
ulcers may be complicated by secondary infection, ﬁbrosis,
and granulomatous inﬂammation in response to fecal mate-
rial.
Stercoral ulcers can present with LGI bleed or features of
acute peritonitis. They are associated with a high mortality
of around 50% [60]. Diagnosis is made by a history of con-
stipation,demonstrationoffecalmasses onabdominalimag-
ing along with colonoscopic and histopathological ﬁndings.
If perforation is suspected, after initial resuscitation and
commencement of prophylactic antibiotics, early deﬁnitive
surgery is warranted. Bleeding ulcers can be successfully
treated with endoscopic procedures, including endoscopic
multipolar electrocoagulation, Argon plasma coagulation
(APC) [61], and injection therapy, [62]. Surgical interven-
tion is indicated in stercoral perforation or failure to control
bleeding.
Inﬂammatory bowel disease (IBD) which includes ulcer-
ative colitis and Crohn’s disease is another important cause
for lower GI bleeding in those with CKD. Although ESRD
patients are not at an increased risk of developing IBD, the
prevalence of this disease within the general population
makes it a signiﬁcant cause of lower GI bleeding in ESRD
patients. Lower GI bleeding is more commonly a presenting
symptom in ulcerative colitis. IBD serology should be care-
fully interpreted in cases of CKD due to the possibility of
underlying vasculitis. The utility of the erythrocyte sedimen-
tation rate as an inﬂammatory marker to predict the disease
ﬂare is also limited in this population because an elevated
ESRis common, in part dueto anemia. Management is simi-
lar as in the general population and depends on the severity
of disease.
Hemorrhoids are common, aﬀecting approximately 4–
10% of the general populationand accounting for up 14% of
the cases of hematochezia [55]. They are the most common
cause of lower GI bleeding in patients under the age of
50 [63]. Hemorrhoids are deﬁned as internal or external
depending on their location above or below the dentate line,
respectively. Theincidenceofhemorrhoids is increased with-
in the peritoneal dialysis patient population due to the in-
creased intra-abdominal pressure experienced during peri-
toneal dialysis [64]. Typically, symptoms increase with the
increasing grade of prolapse and most commonly consist of
intermittent episodes of painless fresh bleeding that streaks
the toilet paper or covers the stools towards the end of defe-
cation [65]. Management of hemorrhoids is based on the
clinical presentation and stage of the disease. Adequate ﬂuid
and ﬁber intake is the primary noninvasive treatment of
symptomatic hemorrhoids but in ESRD patients more ﬂuid
intake can be a problem. Hemorrhoid banding is usually the
most eﬀective option. Other options include sclerotherapy,
infrared coagulation, Bicap coagulation, and cryotherapy.
Infectious diarrhea due to pathogens such as Enterohem-
orrhagic E.coli (EHEC), Shigella, Salmonella, Campylobacter
species, and the protozoan Entamoeba histolytica can cause
visible blood in stools. Generally they can be distinguished
fromothercausesoflowerGIbleedingonthebasisofclinical
setting. Cytomegalovirus (CMV) colitis although uncom-
mon in immunocompetent patients, is important to include
in the diﬀerential diagnosis of immunosuppressed patients
including those with ESRD or postkidney transplantation
[66]. ESRD may also increase the risk of acquiring clostrid-
ium diﬃcile [67] which may cause bloody diarrhea. Treat-
ment is organism speciﬁc based on stool studies.
Uremic colitis is now an entity of historical interest only.
In thepredialysisera,autopsyspecimensofuntreated uremic
patients revealed ulcerations and pseudomembranes, which
were termed uremic colitis. Now, due to the widespread
availability of hemodialysis, this entity is no longer observed
[68].
Spontaneouscolonic perforation in patients with CKD can
occur in association with aluminium-containing antacids,
barium studies, and fecal impaction but some percentage of
cases remains idiopathic [69]. Traditional causes including
diverticulosis should be considered as well. There is a high-
er risk of colonic perforation during colonoscopy among he-
modialysis patients compared with the general population.
Beta2-microglobulin deposition is thought to play role in
colonic perforation [70]. Colonic perforation has a higher
mortality in dialysis patientsas comparedtothegeneralpop-
ulation [69].
In summary, patients with ESRD may develop lower GI
bleeding from a variety of sources. Angiodysplasias are the
most common cause of lower GI blood loss in this popu-
lation but other entities need to be considered as well.
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